Investment Rating - The report maintains a "Positive" investment rating for the industry [2]. Core Insights - NLRP3 inflammasome is identified as a significant target for drug development due to its role as a "receiver and converter" of inflammatory signals, indicating substantial therapeutic potential [11][12]. - NLRP3 inhibitors, particularly VTX3232, have shown remarkable anti-inflammatory effects and preliminary validation for reducing cardiovascular (CV) risks [22][28]. - The market potential for targeting NLRP3 is significant, with a potential patient population of approximately 25 million in the cardiovascular anti-inflammatory drug scenario [39]. Summary by Sections 1. NLRP3 Inflammasome: A Major Drug Target - NLRP3 acts as an intracellular sensor detecting various microbial patterns and endogenous danger signals, leading to the assembly and activation of the NLRP3 inflammasome [11]. - The NLRP3 inflammasome is linked to several common diseases, including obesity, diabetes, and cardiovascular diseases, highlighting the market potential for NLRP3-targeted therapies [12]. 2. Efficacy of NLRP3 Inhibitors - VTX3232 demonstrated a rapid and significant reduction in high-sensitivity C-reactive protein (hsCRP) levels, with an 80% reduction within the first week and a sustained effect over 12 weeks [28]. - The safety profile of VTX3232 is comparable to placebo, with adverse events occurring at similar rates across treatment groups [29]. 3. Identifying Next-Generation NLRP3 Inhibitors - BGE-102, a novel NLRP3 inhibitor, has shown promising early-phase data, indicating its potential to lower hsCRP levels significantly in obese participants [65][67]. - The competitive landscape for NLRP3 inhibitors includes several active candidates, with BGE-102 being highlighted for its unique structure and mechanism [54].

NLRP3："抗炎"能力初步验证，心血管 领域又一潜在重磅靶点 ——美股生物科技前瞻系列 长江证券研究所医药研究小组 2026-02-25 %% %% %% %% research.95579.com 1 分析师及联系人 证券研究报告 • 证券研究报告 • 评级 看好 维持 分析师 彭英骐 分析师 刘长洪 SAC执业证书编号：S0490524030005 SAC执业证书编号：S0490525070007 SFC执业证书编号：BUZ392 %% %% %% %% research.95579.com 2 目 录 01 NLRP3炎症小体：炎症信号的"接收转化 器"，成药潜力巨大 02 NLRP3抑制剂抗炎效果突出，用于降低CV 风险初步验证 03 寻找下一个优质NLRP3抑制剂 04 风险提示 %% research.95579.com 3 01 NLRP3炎症小体：炎症信号的"接收转化器"， 成药潜力巨大 %% %% %% %% research.95579.com 4 NLRP3炎症小体是人体炎症信号的"接收转化器" %% %% %% %% research.95579.com 5 ➢ NLRP3是一种细胞 ...